A phase I open-label multicentre dose-escalation study of subcutaneous ALM201 in patients with advanced ovarian cancer and other solid tumours.

Trial Profile

A phase I open-label multicentre dose-escalation study of subcutaneous ALM201 in patients with advanced ovarian cancer and other solid tumours.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs ALM 201 (Primary)
  • Indications Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Almac Discovery
  • Most Recent Events

    • 11 Oct 2016 Trial design presented at 41st European Society for Medical Oncology Congress.
    • 04 Apr 2015 Status changed from planning to recruiting as per European Clinical Trials Database.
    • 06 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top